Daniela Ungureanu is a CO-PI at the Taipale group in Biomedicum, Helsinki. She received her PhD in Molecular Immunology at the University of Tampere. During her postdoctoral training she transitioned to structural biology and worked on JAK pseudokinases structural and functional characterization and their role in myeloproliferative diseases in the group of Prof. Olli Silvenoinen at the University of Tampere. In 2014 she started her own independent research group (Cancer Signaling) as Academy of Finland Research Fellow working on structural and functional characterization of ROR pseudokinases during cancer development at the University of Tampere.
In 2020, she started as a CO-PI in Taipale group at the Applied Tumor Biology Program in Biomedicum, Helsinki. We take a systems-biology approach to understand how tissue-specific factors collaborate with oncogenic signals to drive cell proliferation in cancer cells. She is also involved in several collaboration projects where the drug testing platform developed at FIMM has been applied to uncover novel drug vulnerabilities in cancer cells.
Koulutus / tieteellinen pätevyys
Molecular and Cellular Biology , Docent (Associate Prof.), University of Tampere
Molecular Immunology , PhD, University of Tampere
Asemat yliopiston ulkopuolella
Cancer Signaling , Tampere University
- 3111 Biolääketieteet
- 318 Lääketieteen bioteknologia
Identifying ovarian cancer specific targeted drugs using high-throughput drug sensitivity profiles of primary cancer cellsMurumagi, A., Hirasawa, A., Khan, S., Ungureanu, D., Arjama, M., Pellinen, T., Eldfors, S., Koivisto-Korander, R., Leminen, A., Butzow, R., Aittokallio, T. & Kallioniemi, O., heinäkuuta 2017, julkaisussa : Cancer Research. 77, Supplement 13, 2 Sivumäärä, 410.
Tutkimustuotos: Artikkelijulkaisu › Konferenssiesitelmän abstrakti › Tutkimus › vertaisarvioitu